Status:
COMPLETED
Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)
Lead Sponsor:
ViiV Healthcare
Collaborating Sponsors:
Pfizer
Conditions:
CCR5-tropic HIV-1 Infection
Eligibility:
All Genders
Brief Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in thi...
Detailed Description
All the patients whom an investigator prescribes the first CELSENTRI® Tablets should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolle...
Eligibility Criteria
Inclusion
- Patients need to be administered CELSENTRI® Tablets in order to be enrolled in the surveillance.
Exclusion
- Patients not administered CELSENTRI® Tablets.
Key Trial Info
Start Date :
March 31 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 24 2018
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT00864474
Start Date
March 31 2010
End Date
December 24 2018
Last Update
January 2 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.